Walter P Beh, MD in Greenville, PA - Urology

Walter P Beh, MD is a Urology physician based in Greenville, Pennsylvania. Walter P Beh is licensed to practice in Pennsylvania (license number MD033115L) and his current practice location is 81 N Main St, Greenville, Pennsylvania. He can be reached at his office (for appointments etc.) via phone at (724) 588-1444.

NPI number for Walter P Beh is 1124020946 and his current mailing address is 81 N Main St, Greenville, Pennsylvania. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1124020946.

Contact Information

	Walter P Beh, MD
	81 N Main St, Greenville, PA 16125-1781
	(724) 588-1444
	(724) 588-1445

Physician's Profile

Full Name	Walter P Beh
Gender	Male
Speciality	Urology
Location	81 N Main St, Greenville, Pennsylvania
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1124020946
Provider Enumeration Date: 08/11/2005
Last Update Date: 03/04/2008

Medical Identifiers

Medical identifiers for Walter P Beh such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1124020946	NPI	-	NPPES
0651414	Medicaid	PA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208800000X	Urology	MD033115L (Pennsylvania)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Walter P Beh is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Walter P Beh, MD 81 N Main St, Greenville, PA 16125-1781 Ph: (724) 588-1444	Walter P Beh, MD 81 N Main St, Greenville, PA 16125-1781 Ph: (724) 588-1444

News Archive

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

Facts about Homecare

Millions of seniors and people living with disabilities will enjoy Thanksgiving and other holidays in the comfort and safety of their own homes thanks to home medical equipment and services such as oxygen therapy, hospital beds, and wheelchairs.

Bone-marrow derived MSCs may reduce acute rejection rates in kidney recipients

Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.

Tuberculosis emergency in Africa

According to the World Health Organisation (WHO), African health ministers have declared a tuberculosis emergency to order to rally greater political commitment in the fight against one of the continent's top killers.

Researchers evaluate cost-effectiveness of osteoporosis screening strategy using FRAX

In new research presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases today, investigators showed that an osteoporosis screening strategy using FRAX as a pre-screening tool is cost-effective if the follow up of the screening and medication adherence are optimized.

Walter P Beh, MD - Urology in Greenville, PA